Literature DB >> 8860069

Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment.

B Frederiksen1, S Lanng, C Koch, N Høiby.   

Abstract

We report survival data for Danish center-treated cystic fibrosis (CF) patients, covering the period 1974-1993 and using cross-sectional cumulative survival probability based on annual age-specific mortality rates. Analyses by age and by years after diagnosis were made. No significant differences were noted in the survival probability when patients were grouped according to sex or absence/presence of meconium ileus. The annual mortality rate for 1989-1993 was 0-1.2%. Using the age-specific mortality rate for 1989-1993, we were unable to calculate the median survival probability because the curve did not fall below 50% (age up to 45 years); however, it was possible to show that the survival probability for a newborn CF child to reach his 45th birthday was 80.4%(confidence interval 76.5-84.6%). The median age at diagnosis was 0.63 years with no sex difference. The probability of surviving 40 years after the diagnosis of CF was made was 83.3% (confidence interval 80.1-86.6%). This is considerably higher than any other published survival probability. An early anti-Pseudomonas aeruginosa treatment regimen seemed important in achieving the observed improved survival.

Entities:  

Mesh:

Year:  1996        PMID: 8860069     DOI: 10.1002/(SICI)1099-0496(199603)21:3<153::AID-PPUL1>3.0.CO;2-R

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  41 in total

Review 1.  Systematic reviews and lifelong diseases.

Authors:  Heather E Elphick; Anton Tan; Deborah Ashby; Rosalind L Smyth
Journal:  BMJ       Date:  2002-08-17

2.  Minimizing the toxicity of aminoglycosides in cystic fibrosis.

Authors:  Alan R Smyth
Journal:  J R Soc Med       Date:  2010-07       Impact factor: 5.344

3.  Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.

Authors:  Sherie Smith; Valerie Waters; Nikki Jahnke; Felix Ratjen
Journal:  Cochrane Database Syst Rev       Date:  2020-06-10

4.  Bone mineral status in 134 patients with cystic fibrosis.

Authors:  E M Laursen; C Molgaard; K F Michaelsen; C Koch; J Müller
Journal:  Arch Dis Child       Date:  1999-09       Impact factor: 3.791

5.  Heterogeneity of biofilms formed by nonmucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  Baoleri Lee; Janus A J Haagensen; Oana Ciofu; Jens Bo Andersen; Niels Høiby; Søren Molin
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

6.  Inferences for health provision from survival data in cystic fibrosis.

Authors:  P A Lewis
Journal:  Arch Dis Child       Date:  1998-10       Impact factor: 3.791

Review 7.  New treatments in adult cystic fibrosis.

Authors:  D Bilton; R Mahadeva
Journal:  J R Soc Med       Date:  1997       Impact factor: 5.344

8.  Scnn1b-Transgenic BALB/c Mice as a Model of Pseudomonas aeruginosa Infections of the Cystic Fibrosis Lung.

Authors:  Kristen J Brao; Brendan P Wille; Joshua Lieberman; Robert K Ernst; Mark E Shirtliff; Janette M Harro
Journal:  Infect Immun       Date:  2020-08-19       Impact factor: 3.441

Review 9.  Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.

Authors:  Christian Krauth; Noushin Jalilvand; Tobias Welte; Reinhard Busse
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 10.  Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis.

Authors:  Andrew Prayle; Alan Watson; Heather Fortnum; Alan Smyth
Journal:  Thorax       Date:  2010-07       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.